Torcetrapib doesn't slow atherosclerosis: study

Share this article:
Pfizer’s experimental compound torcetrapib did not slow progression of plaque buildup in the coronary arteries, despite raising HDL or “good” cholesterol, a study showed. Cleveland Clinic researchers, reporting results of the ILLUSTRATE study at the American College of Cardiology (ACC) in New Orleans, said that a torcetrapib/atorvastatin combination increased good cholesterol and lowered bad cholesterol in patients but substantially raised blood pressure and failed to slow the buildup of plaque. “It is yet to be determined if this failure represents a problem unique to torcetrapib or predicts a lack of efficacy for the entire class of similar drugs,” said Steven Nissen, lead trial investigator, in a statement. Nissen, chairman of cardiovascular medicine at Cleveland Clinic, told Bloomberg he had this advice for other companies with so-called CETP inhibitors in their pipelines, which include Bayer, Roche, Merck and Pfizer: “Now, if we go forward with similar drugs, we should do so in smaller-scale trials, monitored meticulously. We inch our way forward and see if we can't get out of this pickle.” ILLUSTRATE, which involved use of an ultrasound probe to measure the change in plaque, may not have explained why torcetrapib proved ineffective at unclogging arteries. But Pfizer expects to have analyzed all its torcetrapib data by year’s end, and findings from that trial, called ILLUMINATE, may identify the reason the drug failed and if that problem was unique to the compound.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...